VeroScience Late-Breaking Abstract on Cycloset (A Quick Release
Formulation of Bromocriptine Mesylate) Accepted for Poster
Presentation at American Diabetes Association 67th Scientific
TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC,
a privately held biotechnology and healthcare product development
company, announced today that its late-breaking abstract has been
accepted as a poster presentation at the 67th Scientific Sessions
of the American Diabetes Association...
Phase IIIb Clinical Data Validate the Overall and Cardiovascular
Safety Profile of Cycloset (A Quick Release Formulation of
Bromocriptine Mesylate) in Patients with Type 2 Diabetes
Data Also Support Drug's Efficacy at Improving Glycemic Control and
Reducing Diabetic Cardiovascular Complications
CHICAGO, Ill., June 23, 2007 /PRNewswire/ -- VeroScience, LLC,
in conjunction with its commercialization partner S2 Therapeutics,
Inc., reported today the results of its Phase IIIb cl...
Cycloset (Bromocriptine Mesylate Tablets) Drug Information: Uses, Side ...
Learn about the prescription medication Cycloset
(Bromocriptine Mesylate Tablets), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling.
Cycloset: A New Diabetes Drug by RxList
Find out more about the new drug Cycloset
and how it can help treat type 2 diabetes. ... It's not clear how Cycloset
improves glycemic control in humans. ...
Cycloset Information from Drugs.comCycloset
(bromocriptine mesylate) is used to treat Type 2 Diabetes. ... A dopamine agonist, Cycloset
increases dopamine activity. ...
is a prescription medication used for controlling blood sugar in people ... (Click Cycloset
Uses for more information on what the medication is used for, ...
FDA Approves New Diabetes Drug Cycloset
The FDA has approved a new drug, called Cycloset
, to improve blood sugar control in adults with type 2 diabetes, in addition to diet and exercise.
Cycloset prescribing informationCYCLOSET
is a dopamine receptor agonist indicated as an adjunct to diet and ... CYCLOSET
compared to 0.8% of patients randomized to placebo. Among CYCLOSET